PaTHway Phase 3 Trial Analysis

Baseline Albumin-Adjusted Serum Calcium & 24-Hour Urine Calcium Pathway Lab Summary at Baseline TransCon PTH (N = 61) Placebo (N = 21) 61 21 Albumin-Adjusted sCa (mg/dL) (n) Mean (SD) 24-Hour Urine Calcium (mg/dL) (n) Mean (SD) 8.8 (0.7) 60 8.6 (0.6) 392 (175) 21 329 (140) SCA, serum calcium. 14 Data on file, Ascendis Pharma 2022. TransCon PTH is an investigational product candidate. For investor communication only. Not for use in product promotion. Not for further distribution. ascendis pharma TRIAL

View entire presentation